Impacting News- Prohost Biotech - Exclusive Biotech Research

Category: Impacting News

Exelixis Positive Results in Phase 3 CABINET Trial Evaluating Cabozantinib in Advanced Pancreatic and Extra-Pancreatic Neuroendocrine Tumors

Exelixis in the NEWS Exelixis CABOMETYX is approved for the treatment of many cancers. The product has been game changer in the treatment of various difficult to treat cancers before the products that target PD-L1 and approved for several various...

August 26, 2023

Alpine Immune Sciences Treating IgA Nephropathy Among Other Diseases

Alpine Immune Sciences Treating IgA nephropathy Alpine Immune Sciences ( ALPN ) announced a successful initiation of the second IgA nephropathy ( IgAN ) dose cohort in RUBY-3, a phase 1b/2a study in autoimmune glomerulonephritis. The safety Monitoring Committee (SMC)...

August 31, 2023

Publication of Two Cases for Treatment of Metastatic Pancreatic Cancer by CARsgen Therapeutics Holdings Limited

CARsgen Therapeutics Holdings Limited Today, September 21, 2023, CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK ) - a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors, announced the publication of two cases...

September 21, 2023

Soleno Therapeutics Announces Positive Top-Line Results of Its Product DCCR for the Treatment of Prader-Willi Syndrome

Soleno Therapeutics Soleno Therapeutics ( SLNO ) is focused on the development and commercialization of novel therapeutics for the treatment of rare diseases. The company’s lead candidate, DCCR extended-release tablets, a once-daily oral tablet for the treatment of Prader-Willi Syndrome...

September 28, 2023

Akero Therapeutics Announced Publication in the Lancet Gastroenterology & Hepatology of HARMONY Phase 2b Trial Results for NASH

Akero Therapeutics Akero Therapeutics ( AKRO ) announced publication in The Lancet Gastroenterology & Hepatology of results from the HARMONY Phase 2b trial in nonalcoholic steatohepatitis ( NASH ). The paper, which is available online, provides data on the safety,...

October 4, 2023

Apellis Pharmaceuticals Announces Preliminary U.S. Net Revenues of Approximately $74 M for SYFOVRE® in the Q3 2023

Apellis Pharmaceuticals Launch Update of SYFOVRE ® On October 5, 2023, Apellis Pharmaceuticals ( APLS ) provided an update on the launch of its product SYFOVRE® (pegcetacoplan injection) for geographic atrophy ( GA ) secondary to age-related macular degeneration ( AMD...

October 6, 2023

Please Don't Miss Akero Therapeutics Investor Conference Tomorrow, October 10th at 8 AM

Akero Therapeutics to Present Results from Phase 2b SYMMETRY Study Investigating Efruxifermin in Patients with Compensated Cirrhosis Due to NASH Investor webcast on Tuesday, October 10th at 8:00 a.m. ET to present clinical data. Akero Therapeutics ( AKRO )...

October 9, 2023

INOVIO Receives FDA Feedback that Data from Completed Phase 1/2 Trial of INO-3107 Can be Used to Submit a BLA

Inovio Receives FDA Feedback for INO-3107 INOVIO ( INO ) - a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, announced that it received feedback from...

October 11, 2023

Intellia Therapeutics Receives PRIME Designation from the EMA for NTLA-2002 - Investigational In Vivo CRISPR Genome Editing Treatment for Hereditary Angioedema

Intellia Therapeutics Receives PRIME Designation from EMA Intellia Therapeutics ( NTLA ) announced that the European Medicines Agency ( EMA ) has granted Priority Medicine ( PRIME ) designation to its product NTLA-2002. As we already know, NTLA-2002 is an...

October 14, 2023

Anavex Life Sciences Reports Publication in Scientific Journal Demonstrating the Potential of Anavex®3-71 in Preventing Cognitive Decline in Alzheimer's Disease

Anavex Life Sciences NEWS Anavex Life Sciences ( AVXL ) reported a new peer reviewed publication in journal Neurobiology of Aging , titled “ Early treatment with an M1 and sigma 1 receptor agonist prevents cognitive decline in a transgenic rat model displaying Alzheimer-like amyloid pathology ", featuring the orally available small molecule ANAVEX®3-71 (...

October 26, 2023

Search ProhostBiotech

Recent

AstraZeneca Product Fasenra Approved in the US for Eosinophilic Granulomatosis with Polyangiitis

September 19, 2024

The U.S. FDA Approves Novartis' Kisqali® to Reduce the Risk of Recurrence in People with HR+/HER2- Early Breast Cancer

September 18, 2024

AstraZeneca’s Imfinzi + Imjudo Demonstrated Unprecedented Overall Survival in Advanced Liver Cancer

September 17, 2024

Halozyme Therapeutics Announced FDA Approval of Roche’s Tecentriq Hybreza with ENHANZE

September 13, 2024

Johnson & Johnson Product TREMFYA® Receives U.S. FDA Approval

September 12, 2024